Drug Profile
Relatlimab - Bristol-Myers Squibb/Ono Pharmaceuticals
Alternative Names: Anti-LAG-3; Anti-LAG-3 monoclonal antibody - Bristol-Myers Squibb; Anti-LAG-3-Bristol-Myers-Squibb; Anti-lymphocyte activation gene 3 monoclonal antibody; BMS 986016; ONO-4482Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Herlev Hospital; Multiple Myeloma Research Consortium; National Institute of Neurological Disorders and Stroke; Ono Pharmaceutical; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University Hospital of Essen; University of Miami; University of Pittsburgh
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours; Uveal melanoma
- Phase I/II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Fallopian tube cancer; Hodgkin's disease; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Oesophageal cancer; Ovarian cancer; Peritoneal cancer
- Phase I Glioblastoma
Most Recent Events
- 18 Jan 2024 Bristol-Myers Squibb completes the phase I RELATIVITY-111 trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in China (IV) (NCT05498480)
- 03 Oct 2023 National Cancer Institute (NCI) and Bristol Myers Squibb completes a phase-I development in Glioblastoma (Monotherapy, Combination therapy, Recurrent, Second-line therapy or greater) in USA (IV, Infusion) (NCT02658981)
- 26 Jul 2023 Bristol-Myers Squibb completes a phase-I trial in Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Canada, Germany, Spain, Belgium (IV) (NCT03978611) (EudraCT2019-000132-25)